Patrick Ellinor was appointed Director of Editas Medicine, Inc., effective August 6, 2026. As of November 6, 2026, Editas Medicine, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on August 5, 2026, naming 1 appointment (Form 8-K, August 5, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Editas Medicine, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Editas Medicine, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-08-05. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Editas Medicine, Inc. files it.
Also on the record for Editas Medicine, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 27, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 7.8% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G, by ADAR1 Capital Management, LLC | 5.8% of the class | 5%+ stakes | Source |
| July 29, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 4.97% of the class | 5%+ stakes | Source |
| June 3, 2026 | Stake report, Schedule 13G, by RA Capital Management, L.P. | 5.8% of the class | 5%+ stakes | Source |
| June 3, 2026 | Stake report, Schedule 13G, by TCG Crossover GP III, LLC | 9.9% of the class | 5%+ stakes | Source |
| June 2, 2026 | Stake report, Schedule 13G, by Commodore Capital LP | 9.9% of the class | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
Selling to them or working with them? See who runs Editas Medicine, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Editas Medicine, Inc. and the records around it.
Editas Medicine, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Who owns it
Companies that share a holder
- TCG Crossover GP III, LLC also filed stake reports on 3 other companies: Research Alliance Corporation III (Aug 2026), Entera Bio Ltd. (Aug 2026), InflaRx N.V. (May 2026)
- ADAR1 Capital Management, LLC also filed stake reports on 29 other companies: InMed Pharmaceuticals, Inc. (Oct 2026), Tenax Therapeutics, Inc. (Sep 2026), Adagio Medical Holdings, Inc. (Aug 2026)
- Commodore Capital LP also filed stake reports on 40 other companies: Sagimet Biosciences Inc. (Oct 2026), Surrozen, Inc./DE (Oct 2026), JATT III Acquisition Corp (Sep 2026)
Watch Editas Medicine, Inc.
Get an email when Editas Medicine, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Editas Medicine, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Editas Medicine, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Editas Medicine, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-08-05 | In | Director | 2026-08-06 | 8-K, 2026-08-05 |
Who leads Editas Medicine, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Patrick Ellinor, appointed, effective 2026-08-06 (filed 2026-08-05).
New leaders reset buying decisions — get the Full Report on Editas Medicine, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Editas Medicine, Inc., with the record behind each one.
Find candidates like Director at Editas Medicine, Inc.Every change, in the filing's words
Appointed: Patrick Ellinor, Director, effective 2026-08-06
On August 4, 2026, the Board, upon recommendation of the Board's Nominating and Corporate Governance Committee, appointed Patrick Ellinor, M.D., Ph.D. as an independent director, effective August 6, 2026.
- On August 3, 2026, Elliott Levy, M.D., a member of the Board of Directors (the "Board") of the Company who was serving as a class I director, resigned from the Board, effective August 4, 2026.
- The resignation was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
- Dr. Ellinor has been designated as a class I director to serve in accordance with the Company's By-Laws.
- Dr. Ellinor currently serves as Executive Director of the Heart and Vascular Institute at Mass General Brigham, a role he has held since December 2024.
- He has also served as an Institute Member and Director of the Cardiovascular Disease Initiative of the Broad Institute of Harvard and MIT since October 2014, as a Professor of Medicine at Harvard Medical School since July 2003, and as the Telemachus and Irene Demoulas Family Foundation Endowed Chair in Cardiology at Massachusetts General Hospital since June 1998.
- Dr. Ellinor received a B.S. in Biology from the University of Cincinnati and both a Ph.D. in Physiology and an M.D. from Stanford University.
- He did his medical internship and residency at Brigham and Women's Hospital in Boston and completed fellowship training in cardiology and cardiac electrophysiology at Massachusetts General Hospital.
Tools for this story
Each opens in a new tab, filled in for Editas Medicine, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.